GlaxoSmithKline (GSK +0.00%), one of the big pharma companies hit hardest by the patent cliff, is trying to pull ahead by both innovating in the laboratories and innovating its research and development process. In this video, health-care analyst Max Macaluso discusses Glaxo's R&D structure and weighs in on what he expects to see from this drugmaker in 2013.
Can Glaxo Show Its Worth in 2013?
By Max Macaluso – Jan 19, 2013 at 6:00PM
NYSE: GSK
GSK
Market Cap
$89B
Today's Change
(-0.35%) $0.15
Current Price
$43.97
Price as of October 21, 2025 at 1:52 PM ET
Is GlaxoSmithKiline's revolutionary R&D strategy going to work?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo